La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Essex Bio-Technology Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Haizhou Fang

Amministratore delegato

HK$1.7m

Compenso totale

Percentuale dello stipendio del CEO	97.5%
Mandato del CEO	no data
Proprietà del CEO	0.9%
Durata media del management	23.6yrs
Durata media del Consiglio di amministrazione	3.9yrs

Aggiornamenti recenti sulla gestione

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Recent updates

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Haizhou Fang rispetto agli utili di Essex Bio-Technology?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2023	HK$2m	HK$2m	HK$275m
Sep 30 2023	n/a	n/a	HK$266m
Jun 30 2023	n/a	n/a	HK$256m
Mar 31 2023	n/a	n/a	HK$241m
Dec 31 2022	HK$2m	HK$2m	HK$225m
Sep 30 2022	n/a	n/a	HK$274m
Jun 30 2022	n/a	n/a	HK$323m
Mar 31 2022	n/a	n/a	HK$334m
Dec 31 2021	HK$2m	HK$2m	HK$346m
Sep 30 2021	n/a	n/a	HK$339m
Jun 30 2021	n/a	n/a	HK$332m
Mar 31 2021	n/a	n/a	HK$275m
Dec 31 2020	HK$2m	HK$2m	HK$219m
Sep 30 2020	n/a	n/a	HK$221m
Jun 30 2020	n/a	n/a	HK$222m
Mar 31 2020	n/a	n/a	HK$262m
Dec 31 2019	HK$2m	HK$737k	HK$303m
Sep 30 2019	n/a	n/a	HK$282m
Jun 30 2019	n/a	n/a	HK$262m
Mar 31 2019	n/a	n/a	HK$246m
Dec 31 2018	HK$2m	HK$766k	HK$231m
Sep 30 2018	n/a	n/a	HK$210m
Jun 30 2018	n/a	n/a	HK$189m
Mar 31 2018	n/a	n/a	HK$178m
Dec 31 2017	HK$2m	HK$721k	HK$167m

Compensazione vs Mercato: La retribuzione totale di Haizhou ($USD 223.89K ) è inferiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 371.43K ).

Compensazione vs guadagni: La retribuzione di Haizhou è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Haizhou Fang (58 yo)

no data

Mandato

HK$1,744,587

Compensazione

Mr. Haizhou Fang serves as the Managing Director and Executive Director of Essex Bio-Technology Limited and served as its General Manager. Mr. Fang is qualified as a Senior Pharmaceutical Engineer (Profess...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Mia Je Ngiam	Founder & Chairman	no data	HK$3.23m	52.74% HK$ 739.3m
Haizhou Fang	MD & Executive Director	no data	HK$1.74m	0.92% HK$ 13.0m
Hian Leng Ngiam	Executive Director & Deputy MD	no data	HK$1.80m	0.36% HK$ 5.0m
Lai Man Yau	Executive Director & Company Secretary	23.6yrs	HK$755.60k	0.0081% HK$ 113.7k
Qi Xue	Group Chief Scientific Officer	6.3yrs	Nessun dato	Nessun dato

23.6yrs

Durata media

60yo

Età media

Gestione esperta: Il team dirigenziale di 1061 è esperto e expertise (durata media dell'incarico 23.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Mia Je Ngiam	Founder & Chairman	no data	HK$3.23m	52.74% HK$ 739.3m
Haizhou Fang	MD & Executive Director	no data	HK$1.74m	0.92% HK$ 13.0m
Hian Leng Ngiam	Executive Director & Deputy MD	3.9yrs	HK$1.80m	0.36% HK$ 5.0m
Lai Man Yau	Executive Director & Company Secretary	3.9yrs	HK$755.60k	0.0081% HK$ 113.7k
Chi Ying Fung	Independent Non Executive Director	23.2yrs	HK$250.00k	Nessun dato
Mee Mooi Yeow	Independent Non Executive Director	19.9yrs	HK$220.00k	Nessun dato
Man Sing Yan	Independent Non-Executive Director	1.2yrs	HK$128.33k	Nessun dato

3.9yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1061 sono considerati esperti (durata media dell'incarico 3.9 anni).

Essex Bio-Technology Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Recent updates

Essex Bio-Technology Limited to Report First Half, 2024 Results on Aug 26, 2024

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Essex Bio-Technology Limited to Report Fiscal Year 2023 Results on Mar 18, 2024

Investor sentiment deteriorates as stock falls 16%

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.045 per share at 2.0% yield

First half 2023 earnings released: EPS: HK$0.30 (vs HK$0.24 in 1H 2022)

Essex Bio-Technology Limited to Report First Half, 2023 Results on Aug 16, 2023

Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative (Wet) Age-Related Macular Degeneration

Less than half of directors are independent

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 1.8% yield

Now 21% undervalued after recent price drop

Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study

Essex Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Price target decreased to HK$6.00

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Upcoming dividend of HK$0.04 per share

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

First half 2022 earnings released: EPS: HK$0.24 (vs HK$0.28 in 1H 2021)

Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022

Essex Bio-Technology Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021

Price target increased to HK$7.00

Less than half of directors are independent

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.04 per share

First half 2021 earnings released: EPS HK$0.28 (vs HK$0.085 in 1H 2020)

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021 at the Annual General Meeting held on May 12, 2021

Upcoming dividend of HK$0.05 per share

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Essex Bio-Technology Limited Announces Dividend for the Year Ended December 31, 2020, Payable on 1 June 2021

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

Full year 2020 earnings released: EPS HK$0.38 (vs HK$0.52 in FY 2019)

Essex Bio-Technology Limited to Report Fiscal Year 2020 Results on Mar 12, 2021

Investor sentiment improved over the past week

Essex Bio-Technology Limited Announces Positive Outcome of U.S. FDA Second Phase 3 Clinical Trial in Dry Eye Disease

New 90-day high: HK$4.85

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Investor sentiment improved over the past week

New 90-day high: HK$4.40

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

New 90-day low: HK$3.74

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

New 90-day low: HK$3.96

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Executive Director & Company Secretary recently bought HK$193k worth of stock

New 90-day low: HK$3.99